Roche reports strong sales growth in the first nine months of 2017
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. The recently launched medicines Ocrevus, Tecentriq and Alecensa contributed CHF 0.9 billion to new sales, accounting for more than half of the division's growth.
The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries
- Details
- Category: Pfizer
The Union for International Cancer Control (UICC) and Pfizer Oncology have announced the names of the organisations taking part in the second phase of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC MBC Challenge). The 20 organisations from 19 countries that have been selected will receive grants amounting to US$500,000 in funding provided by Pfizer to
A great place to do great things: Developing game-changing technology at Abbott
- Details
- Category: Abbott
Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.
MSD Innovation Factory is looking for digital solutions for anaesthesiologists
- Details
- Category: Business
MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers.
Merck brings customers closer to gene therapy product commercialization
- Details
- Category: Merck Group
Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection.
FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection. The FDA also previously granted Breakthrough Therapy Designation for this application,
More Pharma News ...
- AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
- Pfizer reviewing strategic alternatives for Consumer Healthcare business
- Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
- Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
- Pfizer launches novel programs to put important support services at the fingertips of cancer patients
- Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals
- Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology